TIDMROQ

RNS Number : 8856D

Roquefort Therapeutics PLC

26 June 2023

26 June 2023

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Ajan Reginald, Chief Executive Officer has purchased ordinary shares in the Company, as detailed below:

 
 Number of Ordinary     Average Price   Total Consideration 
             Shares    Paid Per Share                  Paid 
             35,265        7.06 pence           GBP2,489.27 
                     ----------------  --------------------

Following the above purchase of shares, Ajan Reginald holds an interest in 11,663,051 Company ordinary shares.

-ENDS-

Enquiries:

 
  Roquefort Therapeutics plc 
   Stephen West (Chairman) / Ajan          +44 (0)20 3918 
    Reginald (CEO)                                   8633 
   Hybridan LLP (Joint Broker) 
    Claire Louise Noyce 
 
    Optiva Securities Limited (Joint       +44 (0)203 764 
    Broker)                                          2341 
                                           +44 (0)20 3411 
   Christian Dennis                                  1881 
 
    Buchanan (Public Relations) 
    Ben Romney / Jamie Hooper / George     +44 (0)20 7466 
    Beale                                            5000

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

   --    Midkine antibodies with significant in vivo efficacy and toxicology studies; 
   --    Midkine RNA therapeutics with novel anti-cancer gene editing action; 
   --    Midkine mRNA therapeutics with novel anti-cancer approach; 
   --    STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and 
   --    MK cell therapy with direct and NK-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                             Trevor Ajanthan Reginald 
      -------------------------------  --------------------------------------------- 
       Reason for the notification 
  2 
      ------------------------------------------------------------------------------ 
 a)    Position/status                  Chief Executive Officer 
      -------------------------------  --------------------------------------------- 
 b)    Initial notification             Initial 
        /Amendment 
      -------------------------------  --------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------ 
 a)    Name                             Roquefort Therapeutics plc 
      -------------------------------  --------------------------------------------- 
 b)    LEI                              254900P4SISIWOR9RH34 
      -------------------------------  --------------------------------------------- 
       Details of the transaction(s): section to be repeated 
  4     for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------ 
 a)    Description of the               Ordinary shares of GBP0.01 par value 
        financial instrument, 
        type of instrument               ISIN: GB00BMDQ2T15 
        Identification code 
      -------------------------------  --------------------------------------------- 
 b)    Nature of the transaction        Purchase of 35,265 ordinary shares 
      -------------------------------  --------------------------------------------- 
 c)    Price(s) and volume(s)           Price(s)                        Volume(s) 
      -------------------------------  -------------------------------  ------------ 
                                        7.08 pence per share                  28,715 
    7.08 pence per share                                                       2,600 
    6.94 pence per share                                                       2,600 
    6.91 pence per share                                                       1,350 
  --------------------------------------------------------------------  ------------ 
 d     Aggregated information 
        - Aggregated volume                     *    35,265 
        - Price 
 
                                                *    7.06p 
      -------------------------------  --------------------------------------------- 
 e)    Date of the transactions         23 June 2023 (33,915 shares) and 26 
                                         June 2023 (1,350 shares) 
      -------------------------------  --------------------------------------------- 
 f)    Place of the transactions        28,715 purchased off-market 
                                         6,550 purchased on London Stock Exchange 
                                         (XLON); Main Market 
      -------------------------------  ---------------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGIGDLUUDDGXL

(END) Dow Jones Newswires

June 26, 2023 05:00 ET (09:00 GMT)

Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Roquefort Therapeutics.
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Roquefort Therapeutics.